secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-261665
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec gets FDA Fast Track for BB-301 in OPMD; 100% response rate in Cohort 1
------------------------------------------------------------------------------

- FDA granted Fast Track Designation to BB-301 for OPMD with dysphagia; BB-301 also has Orphan Drug Designation from FDA and EMA.
- All six Cohort 1 patients met statistical response criteria (100% response rate) with significant improvements in dysphagia measures.
- First Cohort 2 patient treated in Q4 2025; Benitec plans FDA meeting in 2026 to confirm pivotal study design.
- Appointed Dr. Sharon Mates to board; she was co-founder/CEO of Intra-Cellular Therapies (acquired by JNJ for ~$14.6B in 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525261665/0001193125-25-261665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525261665/bntc-20251102.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-261665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer